TYK2 inhibitors may offer pathway for more comprehensive inflammation therapy
The emergence of drugs inhibiting the JAK-STAT pathway has culminated in tyrosine kinase 2 inhibitors targeting psoriatic arthritis, lupus and other indications, noted a presenter at the 2022 Association of Women in Rheumatology conference.“Now we have TYK2, which is involved in the pathogenesis of many immune-mediated diseases,” Grace C. Wright, MD, PhD, FACR, president of the Association of Women in Rheumatology, told attendees during the hybrid meeting. “What we are seeing, depending on how you disrupt that pathway, was a lack of serious adverse events associated withRead More
